Moreover, since prior reports showed that TLR2-TRAF6 activation suppresses oncogenic MYC activity in myeloid malignancies (40), we tested whether the TLR2 agonist CU-T12-9 reduces MYC’s association with the FBXO11 promoter. Here, TRAF6 is linked to myeloid neoplasm.